Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | MAP2K1 |
| Variant | R47Q |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | MAP2K1 R47Q lies within the negative regulatory region of the Map2k1 protein (PMID: 24241536). R47Q results in increased phosphorylation of Erk and is transforming in cell culture (PMID: 22327936). |
| Associated Drug Resistance | |
| Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 R47Q |
| Transcript | NM_002755.4 |
| gDNA | chr15:g.66435086G>A |
| cDNA | c.140G>A |
| Protein | p.R47Q |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002755 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| XM_017022411.3 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| NM_002755.3 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| NM_002755.4 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| XM_017022411.2 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| XM_017022411 | chr15:g.66435086G>A | c.140G>A | p.R47Q | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MAP2K1 R47Q | melanoma | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478). | 36442478 |
| BRAF V600E MAP2K1 R47Q | melanoma | sensitive | Binimetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mektovi (binimetinib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478). | 36442478 |
| BRAF V600E MAP2K1 R47Q | melanoma | sensitive | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Tafinlar (dabrafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478). | 36442478 |
| BRAF V600E MAP2K1 R47Q | melanoma | sensitive | Encorafenib | Preclinical - Cell culture | Actionable | In a preclinical study, Braftovi (encorafenib) inhibited viability of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 R47Q in culture (PMID: 36442478). | 36442478 |